Sheila S McThenia1, Neeta Pandit-Taskar2, Milan Grkovski3, Maria A Donzelli1, Safiatu Diagana1, Jeffrey P Greenfield4, Mark M Souweidane4, Kim Kramer5. 1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Deptartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Weill Cornell Medical College, New York, NY, USA. 5. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kramerk@mskcc.org.
Abstract
PURPOSE: Programmable ventriculoperitoneal shunts (pVP shunts) are increasingly utilized for intraventricular chemotherapy, radioimmunotherapy, and/or cellular therapy. Shunt adjustments allow optimization of drug concentrations in the thecal space with minimization in the peritoneum. This report assesses the success of the pVP shunt as an access device for intraventricular therapies. Quantifying intrathecal drug delivery using scintigraphy by pVP shunt model has not been previously reported. METHODS: We performed a single-institution, retrospective analysis on patients with CNS tumors and pVP shunts from 2003 to 2020, noting shunt model. pVP flow was evaluated for consideration of compartmental radioimmunotherapy (cRIT) using In-111-DTPA scintigraphy. Scintigraphy studies at 2-4 h and at 24 h quantified ventricular-thecal and peritoneal drug activity. RESULTS: Twenty-two CSF flow studies were administered to 15 patients (N = 15) with diagnoses including medulloblastoma, metastatic neuroblastoma, pineoblastoma, and choroid plexus carcinoma. Six different types of pVP models were noted. 100% of the studies demonstrated ventriculo-thecal drug activity. 27% (6 of 22) of the studies had no peritoneal uptake visible by imaging. 73% (16 of 22) of the studies had minimal relative peritoneal uptake (< 12%). 27% (6 of 22) of the studies demonstrated moderate relative peritoneal uptake (12-37%). No studies demonstrated peritoneal uptake above 37%. CONCLUSIONS: All patients had successful drug delivery of In-111-DTPA to the ventriculo-thecal space. 73% of the patients had minimal relative (< 12%) peritoneal drug uptake. Though efficacy varies by shunt model, low numbers preclude conclusions regarding model superiority. CSF flow scintigraphy studies assesses drug distribution of In-111-DTPA, informing CSF flow for delivery of intraventricular therapies.
PURPOSE: Programmable ventriculoperitoneal shunts (pVP shunts) are increasingly utilized for intraventricular chemotherapy, radioimmunotherapy, and/or cellular therapy. Shunt adjustments allow optimization of drug concentrations in the thecal space with minimization in the peritoneum. This report assesses the success of the pVP shunt as an access device for intraventricular therapies. Quantifying intrathecal drug delivery using scintigraphy by pVP shunt model has not been previously reported. METHODS: We performed a single-institution, retrospective analysis on patients with CNS tumors and pVP shunts from 2003 to 2020, noting shunt model. pVP flow was evaluated for consideration of compartmental radioimmunotherapy (cRIT) using In-111-DTPA scintigraphy. Scintigraphy studies at 2-4 h and at 24 h quantified ventricular-thecal and peritoneal drug activity. RESULTS: Twenty-two CSF flow studies were administered to 15 patients (N = 15) with diagnoses including medulloblastoma, metastatic neuroblastoma, pineoblastoma, and choroid plexus carcinoma. Six different types of pVP models were noted. 100% of the studies demonstrated ventriculo-thecal drug activity. 27% (6 of 22) of the studies had no peritoneal uptake visible by imaging. 73% (16 of 22) of the studies had minimal relative peritoneal uptake (< 12%). 27% (6 of 22) of the studies demonstrated moderate relative peritoneal uptake (12-37%). No studies demonstrated peritoneal uptake above 37%. CONCLUSIONS: All patients had successful drug delivery of In-111-DTPA to the ventriculo-thecal space. 73% of the patients had minimal relative (< 12%) peritoneal drug uptake. Though efficacy varies by shunt model, low numbers preclude conclusions regarding model superiority. CSF flow scintigraphy studies assesses drug distribution of In-111-DTPA, informing CSF flow for delivery of intraventricular therapies.
Authors: Mark M Souweidane; Kim Kramer; Neeta Pandit-Taskar; Zhiping Zhou; Sofia Haque; Pat Zanzonico; Jorge A Carrasquillo; Serge K Lyashchenko; Sunitha B Thakur; Maria Donzelli; Ryan S Turner; Jason S Lewis; Nai-Kong V Cheung; Steven M Larson; Ira J Dunkel Journal: Lancet Oncol Date: 2018-06-18 Impact factor: 41.316
Authors: Kayleen Bailey; Neeta Pandit-Taskar; John L Humm; Pat Zanzonico; Stephen Gilheeney; Nai-Kong V Cheung; Kim Kramer Journal: J Neurooncol Date: 2019-03-16 Impact factor: 4.130
Authors: David S Hersh; Aniket S Wadajkar; Nathan Roberts; Jimena G Perez; Nina P Connolly; Victor Frenkel; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim Journal: Curr Pharm Des Date: 2016 Impact factor: 3.116
Authors: Evgenii Belykh; Kurt V Shaffer; Chaoqun Lin; Vadim A Byvaltsev; Mark C Preul; Lukui Chen Journal: Front Oncol Date: 2020-06-05 Impact factor: 6.244